Prognostic factors in ovarian cancer: current evidence and future prospects (Q57200529)

2

0 references

J.P Schouten

3

0 references

H.J.G. Arts

4

0 references

R.M.W. Hofstra

5

0 references

P.H.B. Willemse

6

0 references

E.G.E. de Vries

7

0 references

A.G.J. van der Zee

8

0 references

publication date

September 2003

0 references

published in

EJC supplements

0 references

volume

1

0 references

issue

6

0 references

page(s)

127-145

0 references

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Epidermal growth factor enhances cisplatin-induced apoptosis by a caspase 3 independent pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Are DNA ploidy and epidermal growth factor receptor prognostic factors for untreated ovarian cancer? A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

1 reference

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Prognostic significance of c-erB-2 mRNA in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Extracellular glutathione is a source of cysteine for cells that express gamma-glutamyl transpeptidase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione S-transferase: genetics and role in toxicology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione S-transferase expression in benign and malignant ovarian tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Immunohistochemical expression of glutathione S-transferase pi (GST-pi) and chemotherapy response in malignant ovarian tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 accumulation in ovarian carcinomas and its prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Prognostic significance of p53 immunostaining in epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The combined evaluation ofp53 accumulation and of Ki-67 (MIBI) labelling index provides independent information on overall survival of ovarian carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

P53 mutation does not affect prognosis in ovarian epithelial malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Prognostic value of p53 accumulation in epithelial ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The Sequence of the Human Genome

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Ethnic differences in survival among women with ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Significance of epidermal growth factor receptor in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Multiple drug resistance parameter expression in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Quantification of p53 in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 mutations and expression in ovarian cancers: correlation with overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2803%2990017-6

7 January 2021